Trial Profile
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Zorifertinib (Primary) ; Erlotinib; Gefitinib
- Indications Brain metastases; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms EVEREST
- Sponsors Alpha Biopharma
- 06 Jun 2023 Primary endpoint has been met (PFS assessed by Blinded Independent Central Radiological) , according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (as of 12 Jul 2022, at median follow-up 20.4 months) reporting safety and efficacy presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 29 Jan 2023 According to an Alpha Biopharma media release, Professor Yilong Wu, President of the Chinese Thoracic Oncology Group (CTONG) is a leading principal investigator of this study.